Remove tag uk
article thumbnail

Oligonucleotide synthesis market to reach $16.7 billion by 2027

European Pharmaceutical Review

LGC Limited (UK). Tag Copenhagen A/S (Denmark). Alnylam Pharmaceuticals, Inc. (US). ATDBio Ltd. ( Biogen Inc. (US). Biolegio B.V. Netherlands). Biolytic Lab Performance Inc. (US). CSBIO (US). Danaher Corporation (US). Eton Bioscience, Inc. (US). Eurofins Scientific (Germany). Ionis Pharmaceuticals, Inc. (US).

article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

This is not the first treatment to come with a high price tag. Countries with a high willingness for performance-based models, such as the UK, saw this RSA type peak in 2019 before continually declining. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

Marketing 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Free access to Zolgensma curbed, says Novartis

pharmaphorum

” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1 Pause in UK access. million in the US and just under €2 million in Europe, which the company says is justified by its dramatic benefits when given as a one-shot therapy to patients with SMA. .

article thumbnail

Cannabinoids receptors: popular preclinical target but banned in 137 countries

Pharmaceutical Technology

Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. In most EU and Commonwealth countries, including the UK, New Zealand and Australia, cannabinoids are legal for medical use.

Medical 98
article thumbnail

Orphan drugs and where to launch them: The keys to Europe’s forgotten territories

Pharmaceutical Technology

Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). The choice of where to launch an orphan drug is an important and difficult decision.

article thumbnail

J&J builds case for antidepressant Spravato with head-to-head trial

pharmaphorum

One issue has been the cost of the drug, with health technology assessment agency NICE in the UK and the ICER organisation in the US both concluding its price tag means it is not a cost-effective option for health systems.

Sales 52
article thumbnail

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

High-prescribing physicians surveyed by GlobalData across eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China) identified a broad range of unmet needs in the IO space (see Figure 1). Despite the significant advances that have been made in the IO field, a huge level of unmet need remains.